DB
ARLZ

Dmitry Balyasny’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Dmitry Balyasny’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-16,390
Closed -$25K – 2405
2018
Q1 		$25K Buy
+16,390
New +$28.6K ﹤0.01% 1876

Other funds holding ARLZ

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
SM
Salzhauer Michael $292M AUM 30% 1-Year Est. Return
PCM
PAR Capital Management Boston, Massachusetts $4.03B AUM 35.05% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
SCP
Silverleafe Capital Partners Germantown, Tennessee $367M AUM 37.49% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Dmitry Balyasny's ARLZ Position: Q2 2018 in Review

Dmitry Balyasny sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q2 2018, closing a stake of 16,390 shares — an estimated $25K sold.

Dmitry Balyasny first reported a position in ARLZ in Q1 2018 and held it in 1 quarter. The position peaked at $25K in Q1 2018. 48 funds tracked by Wall St. Rank hold ARLZ as of Q2 2018.

  • Dmitry Balyasny reported no remaining Aralez Pharmaceuticals Inc. position as of Q2 2018 after selling out during the quarter.
  • Dmitry Balyasny sold 16,390 Aralez Pharmaceuticals Inc. shares in Q2 2018, an estimated $25K.
  • Dmitry Balyasny first reported a position in Aralez Pharmaceuticals Inc. in Q1 2018 and held it in 1 quarter.
  • Dmitry Balyasny's Aralez Pharmaceuticals Inc. position peaked at $25K in Q1 2018.
  • 48 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q2 2018.

Based on Balyasny Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.